653O Pembrolizumab (pembro) Vs Placebo As Adjuvant Therapy for Patients (pts) with Renal Cell Carcinoma (RCC): Patient-reported Outcomes (PRO) in KEYNOTE-564

Toni K. Choueiri,Piotr Tomczak,S.H. Park,Balaji Venugopal,Stefan Symeonides,Jaroslav Hájek,Thomas Ferguson,Y-H. Chang,J.L. Lee,Naomi B. Haas,Piotr Sawrycki,Naveed Sarwar, Marine Gross‐Goupil, A. Thiery-Vuillemin, Mauricio Mahave, Todd L. Saretsky,P. Zhang,Jaqueline Willemann-Rogerio,David I. Quinn,Thomas Powles

Annals of oncology（2021）

引用 4|浏览0

暂无评分

摘要

The randomized, double-blind, phase III KEYNOTE-564 (NCT03142334) study met its primary endpoint of disease-free survival with adjuvant pembro vs placebo following surgery in pts with RCC. We present PRO findings for adjuvant pembro vs placebo in KEYNOTE-564.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要